Breaking News
April 26, 2018 - FDA Alert: Lamictal (lamotrigine): Drug Safety Communication
April 26, 2018 - Massive single-cell survey of kidney cell types reveals new paths to disease
April 26, 2018 - Cognitive behavioral therapy can help children with autism manage emotional challenges
April 26, 2018 - CU Anschutz Medical Campus receives NIH grant to speed up discovery of new treatments
April 26, 2018 - Researchers discover significant distortions in leading genetics study method
April 26, 2018 - New combination therapy could improve survival in children with high-risk neuroblastoma
April 26, 2018 - Scientists clarify casual role of oxidative stress in metabolically abnormal and healthy obesities
April 26, 2018 - Home-based exercise program found ineffective for patients with peripheral artery disease
April 26, 2018 - Choroidal Thickness Changes in Patients With Untreated DM
April 26, 2018 - Medical chemists discover peptic ulcer treatment metallodrug effective in ‘taming’ superbugs
April 26, 2018 - UB researchers build 3D-printed, drug-filled dentures to fight against infections
April 26, 2018 - Researchers find role of iron storage gene in slowing down prostate cancer growth
April 26, 2018 - Study suggests link between regular mid-day naps and neurocognitive function in teens
April 26, 2018 - Researchers gain ground-breaking insights into how inflammatory diseases work
April 26, 2018 - Injured U.S. Vet Receives World’s First Penis/Scrotum Transplant
April 26, 2018 - Researchers find existing drug effective at preventing onset of type 1 diabetes
April 26, 2018 - MGH researchers identify risk factors for drug overdose in youth with substance use disorders
April 26, 2018 - Researchers develop new vaccine to help people overcome bath salts abuse
April 26, 2018 - Genetic signature predicts diabetes diagnosis
April 26, 2018 - Study shows link between restless legs syndrome symptoms and brain structure
April 26, 2018 - MU researchers use new techniques to fight against diabetic retinopathy
April 26, 2018 - AAE’s new practice statements aim at improving patient care
April 26, 2018 - Expression of long non-coding RNAs can result in high levels of specific proteins involved in cancer
April 26, 2018 - FDA re-examining safety of new drug approved for Parkinson’s disease psychosis
April 26, 2018 - Unanimous Positive Result of FDA Advisory Committee Meeting for First Plant-Based Pharmaceutical Cannabidiol Treatment for Seizures in Patients with Two Rare, Severe Forms of Epilepsy
April 26, 2018 - Bacteria boost antifungal drug resistance in severe childhood tooth decay
April 26, 2018 - New study affirms bedtime habits of Americans
April 26, 2018 - Hospital patients are more interested in tracking their health data, research shows
April 26, 2018 - Study shows gene variations associated with malaria risk
April 26, 2018 - Inhealthcare teams up with MSKassist to combat problems related to obesity and aging
April 26, 2018 - Caffeine during pregnancy – babies 66 percent more likely to become overweight
April 26, 2018 - FDA Approves Jynarque (tolvaptan) to Slow Kidney Function Decline in Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease
April 26, 2018 - Pricey dental implants often best but insurance rarely pays
April 26, 2018 - Advion’s Peak Express software now available with the expression compact mass spectrometer
April 25, 2018 - Researchers find link between pneumonia in older people and PPI prescriptions
April 25, 2018 - Alcohol damages microbiome in the mouth
April 25, 2018 - Regular soaking in hot tub improves health outlook in obese women with PCOS
April 25, 2018 - FDA Alert: Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT) Devices: Letter to Health Care Providers
April 25, 2018 - Sunshine could hold clues on the timing for a severe form of heart attack, study says
April 25, 2018 - Sartorius Stedim Biotech launches mini bioreactor vessel for ambr 250 high throughput system
April 25, 2018 - Biofeedback-assisted relaxation may help children during medical procedures
April 25, 2018 - Key signaling protein in Huntington’s disease found to have deleterious effects on heart function, shows study
April 25, 2018 - Celecoxib Lowers Opioid Use Post Head & Neck Cancer Surgery
April 25, 2018 - New ‘brain health index’ can predict how well patients will do after stroke
April 25, 2018 - Positive interventions in sepsis management raise key questions about E. coli reduction targets
April 25, 2018 - Scientists identify new DNA structure within living human cells
April 25, 2018 - E. coli’s toxin-antitoxin system inhibits bacterial growth
April 25, 2018 - Researchers uncover reason why exercise may be beneficial for the heart
April 25, 2018 - Researcher presents case study of asymptomatic patient with severe mitral regurgitation
April 25, 2018 - Use ‘Proper Form’ When Practicing Yoga
April 25, 2018 - Study reports possible novel method for stopping untreatable pediatric brain cancers
April 25, 2018 - Visually guided walking paves way for better treatment for mobility impairments
April 25, 2018 - Researchers identify novel pathway in development of AML with poor prognosis
April 25, 2018 - Cardiovascular disease may only be a matter of time for people with healthy obesity
April 25, 2018 - Girls with type 2 diabetes have high frequency of menstrual irregularities
April 25, 2018 - Study explains why intense exercise curbs appetite
April 25, 2018 - Experimental drug for rheumatoid arthritis prevents side effect of stem cell transplants
April 25, 2018 - Why are Antibiotics Overprescribed for Meningitis Treatment?
April 25, 2018 - Consuming protein supplements with meals, rather than between meals, may promote weight control
April 25, 2018 - Seeing prostate cancer in a new light
April 25, 2018 - Jacobs Medical Center recognized with Baby Friendly Designation for efforts in mother-baby bonding
April 25, 2018 - Gene related to high fatality could be used as biomarker in patients with P. aeruginosa infection
April 25, 2018 - Study shows patients in major prostate cancer study are more likely to die than real-world patients
April 25, 2018 - HBP researchers develop new tool to examine role of genes in disease-relevant brain regions
April 25, 2018 - Trio’s pioneering silicone ostomy product wins prestigious Queen’s Award for Enterprise
April 25, 2018 - Study highlights potential of stem cells derived from adults in regenerative medicine
April 25, 2018 - A new, emerging procedure burns cancer cells
April 25, 2018 - Acclarent introduces real-time, 3D navigation system for ENT procedures
April 25, 2018 - Italy’s prestigious Veneto Institute of Oncology acquires MILabs’ latest VECTor5CT system
April 25, 2018 - Future screening is more likely for people with false-positive cancer screening results
April 25, 2018 - Tweezers made of laser beams manipulate atoms to make new molecules
April 25, 2018 - Elevated immune function during childhood linked to stunted growth
April 25, 2018 - FDA Accepts New Drug Application for Duvelisib and Grants Priority Review
April 25, 2018 - Research reveals autism and schizophrenia share common traits
April 25, 2018 - Perceived stress decreases for most women over 15-year span, study finds
April 25, 2018 - Coastal Genomics’ LightBench integrated with Hamilton liquid handler systems to bring efficiencies, savings for clinical laboratories
April 25, 2018 - Researchers discover new gene associated with aortic aneurysms
April 25, 2018 - Preantral zinc deficiency may affect fertility months
April 25, 2018 - Repurposing existing antiviral drugs for multiple infections
April 25, 2018 - Can GAC Be Used to Control Priority Unregulated DBPs in Drinking Water?
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation

U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation

image_pdfDownload PDFimage_print

prucalopride

Treatment for Chronic Idiopathic Constipation

U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation

Cambridge, Mass. – March 5, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the U.S. Food and Drug Administration (FDA) has accepted the submission of a New Drug Application (NDA) for prucalopride (also known as SHP555). Prucalopride is being evaluated as a potential once-daily treatment option for chronic idiopathic constipation (CIC) in adults. The FDA is expected to provide a decision on or around December 21, 2018, the designated Prescription Drug User Fee Act (PDUFA) action date with FDA noting that timelines are flexible and subject to change based on workload and identification of potential review issues.

“Today’s acceptance of the NDA reinforces the breadth and depth of Shire’s capabilities in gastrointestinal conditions and commitment to providing new treatment options for patients living with hard-to-treat conditions,” said Andreas Busch, Ph.D., Head of Research and Development at Shire. “If approved by the FDA, prucalopride will be the only readily available 5-HT4 agonist1 in the United States for chronic idiopathic constipation in adults. We look forward to working with the FDA as the agency reviews our application.”

There is an estimated 35 million people in the United States with chronic idiopathic constipation.2,3 The condition is characterized by difficult, infrequent or incomplete passage of stools over a prolonged period and a range of symptoms, which may include abdominal pain and/or bloating.4 There are many causes, and one of the possible underlying problems is an impairment or dysfunction of the gut’s ability to move, by contracting and releasing, naturally.5

“Chronic idiopathic constipation is a commonly-occurring condition that affects nearly one in eight people in the United States,”2,3 said William D. Chey, M.D., Professor of Gastroenterology & Nutrition Sciences, and Director of the GI Nutrition & Behavioral Wellness Program at the University of Michigan Health System, Ann Arbor. “Many patients use over-the-counter and prescription medicines, including laxatives, but continue to have constipation symptoms.”6

For more than 10 years, Shire has demonstrated its commitment to the GI community and cultivated deep in-house capabilities and expertise in the category. Through a diversified portfolio and growing pipeline, Shire aims to extend its GI footprint to new indications and therapeutic areas to meet the needs of patients living with rare and specialized GI conditions.

Prucalopride, a high affinity, selective serotonin type 4 (5‑HT4) receptor agonist, is a gastrointestinal prokinetic agent that stimulates colonic peristalsis, increasing bowel motility.7,8 Prucalopride has been studied in more than 90 clinical trials worldwide over the last 20 years, including five main Phase 3 and one Phase 4 double-blind, placebo-controlled clinical trials that informed the NDA submission.

An integrated analysis of the six, main randomized, controlled clinical trials evaluated the global efficacy and safety of prucalopride 2 mg daily in men and women with chronic constipation; study designs across the trials were similar. Overall, there were 2,484 adult patients included in the integrated efficacy analysis and 2,552 adult patients included in the integrated safety analysis; all patients included received prucalopride ≤2 mg/day or placebo. Significantly more patients treated with prucalopride versus placebo (27.8% vs 13.2%; p9

Shire conducted an observational, pharmacoepidemiology safety study to estimate, in real-world settings, the risk of major adverse cardiovascular events (MACE) in patients treated with prucalopride compared to patients treated with polyethylene glycol (PEG). Drugs similar to prucalopride have been associated with adverse cardiovascular events in the past. Study results are included in the NDA to provide the FDA additional understanding of the CV safety profile of prucalopride.10

The FDA’s acceptance of the prucalopride NDA reinforces Shire’s breadth and depth of its therapeutic areas expertise in bringing possible treatment options to patients. In 2017 alone, Shire received either Breakthrough Therapy, Orphan Drug, Priority Review or Fast Track designations by the FDA for five of its therapies and anticipates continued progress of key regulatory milestones for late-stage programs.

About Prucalopride

Prucalopride is an investigational compound, and has not been approved for use by the U.S. Food and Drug Administration.

Prucalopride currently is approved and available in the European Union (EU) where it is marketed by Shire as Resolor®, indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.11 It is also available in several other countries outside of Europe.

About Shire GI

Shire has a long-standing heritage in gastrointestinal (GI) conditions. With a rich and diversified portfolio, we seek to transform the outlook of patients living with rare and hard to treat GI conditions by helping to address unmet needs. For more than 10 years, we have made a continued commitment to the GI community, and to cultivating a deep in-house expertise in the category. Through a growing pipeline, Shire aims to extend its GI portfolio to new indications and therapeutic areas to meet the needs of adult and pediatric patients living with rare and specialized GI conditions.

About Shire

Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey.

Forward-Looking Statements

Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, projected revenues, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:

Shire’s products may not be a commercial success;
increased pricing pressures and limits on patient access as a result of governmental regulations and market developments may affect Shire’s future revenues, financial condition and results of operations;
Shire depends on third parties to supply certain inputs and services critical to its operations including certain inputs, services and ingredients critical to its manufacturing processes. Any disruption to the supply chain for any of Shire’s products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time;
the manufacture of Shire’s products is subject to extensive oversight by various regulatory agencies. Regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to, among other things, significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
the nature of producing plasma-based therapies may prevent Shire from timely responding to market forces and effectively managing its production capacity;
Shire has a portfolio of products in various stages of research and development. The successful development of these products is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval;
the actions of certain customers could affect Shire’s ability to sell or market products profitably. Fluctuations in buying or distribution patterns by such customers can adversely affect Shire’s revenues, financial conditions or results of operations;
failure to comply with laws and regulations governing the sales and marketing of its products could materially impact Shire’s revenues and profitability;
Shire’s products and product candidates face substantial competition in the product markets in which it operates, including competition from generics;
Shire’s patented products are subject to significant competition from generics;
adverse outcomes in legal matters, tax audits and other disputes, including Shire’s ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on the Shire’s revenues, financial condition or results of operations;
Shire may fail to obtain, maintain, enforce or defend the intellectual property rights required to conduct its business;
Shire faces intense competition for highly qualified personnel from other companies and organizations;
failure to successfully execute or attain strategic objectives from Shire’s acquisitions and growth strategy may adversely affect the Shire’s financial condition and results of operations;
Shire’s growth strategy depends in part upon its ability to expand its product portfolio through external collaborations, which, if unsuccessful, may adversely affect the development and sale of its products;
a slowdown of global economic growth, or economic instability of countries in which Shire does business, could have negative consequences for Shire’s business and increase the risk of non-payment by Shire’s customers;
changes in foreign currency exchange rates and interest rates could have a material adverse effect on Shire’s operating results and liquidity;
Shire is subject to evolving and complex tax laws, which may result in additional liabilities that may adversely affect the Shire’s financial condition or results of operations;
if a marketed product fails to work effectively or causes adverse side effects, this could result in damage to Shire’s reputation, the withdrawal of the product and legal action against Shire;
Shire is dependent on information technology and its systems and infrastructure face certain risks, including from service disruptions, the loss of sensitive or confidential information, cyber-attacks and other security breaches or data leakages that could have a material adverse effect on Shire’s revenues, financial condition or results of operations;
Shire faces risks relating to the expected exit of the United Kingdom from the European Union;
Shire incurred substantial additional indebtedness to finance the Baxalta acquisition, which has increased its borrowing costs and may decrease its business flexibility;
Shire’s ongoing strategic review of its Neuroscience franchise may distract management and employees and may not lead to improved operating performance or financial results; there can be no guarantee that, once completed, Shire’s strategic review will result in any additional strategic changes beyond those that have already been announced; and
a further list and description of risks, uncertainties and other matters can be found in Shire’s most recent Annual Report on Form 10-K and in Shire’s subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in “ITEM1A: Risk Factors”, and in Shire’s subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire’s website.

All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

1 Briejer MR et al. Eur J Pharmacol 2001;423:71–83.
2 US Census Data. Available at: https://www.census.gov/quickfacts/fact/table/US/PST045216. 2016 (NOTE: estimate of 35 million based on US adult population of 248.71 million divided by CIC incidence of 14% from reference 3)
3 Suares NC, Ford AC. Prevalence of, and Risk Factors for, Chronic Idiopathic Constipation in the Community: Systematic Review and Meta-analysis. The American Journal of Gastroenterology 2011;106:1582-1591.
4 Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology 2016;150:1393–407.
5 Ford AC, Moayyedi P, Lacy BE, et. al. American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. Am J Gastroenterol 2014;109:S2 – S26.
6 Johanson, J. F. and Kralstein, J. (2007), Chronic constipation: a survey of the patient perspective. Alimentary Pharmacology & Therapeutics, 25: 599–608. doi:10.1111/j.1365-2036.2006.03238.
7 Camilleri, M, et al. 2008 A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation. N Engl J Med. 2008;358:2344-2354.
8 Miner, PB, Camilleri, M., Burton, D., et. al. Prucalopride induces high-amplitude propagating contractions in the colon of patients with chronic constipation: a randomized study. Neurogastroenterol. Motil. 2016;28:(9):1341-1348.
9 Camilleri M, et al. Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials. Digestive Diseases and Sciences. 2016.61:2357-2372.
10 European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Cohort Study of the Relative Incidence of Major Cardiovascular Events Among Patients Initiating Prucalopride Versus a Matched Comparator Cohort..Available at: http://www.encepp.eu/encepp/viewResource.htm?id=22643. Accessed March 5, 2018.
11 Resolor® (prucalopride), EU Summary of Product Characteristics, December 2015.

*This represents ~14% of the U.S. population as of July 1, 2016 Census Bureau Data.

Source: Shire plc

Posted: March 2018

prucalopride FDA Approval History

Tagged with:

About author

Related Articles